AbbVie 2013 Annual Report Download - page 45

Download and view the complete annual report

Please find page 45 of the 2013 AbbVie annual report below. You can navigate through the pages in the report by either clicking on the pages listed below, or by using the keyword search tool below to find specific information within the annual report.

Page out of 176

  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • 7
  • 8
  • 9
  • 10
  • 11
  • 12
  • 13
  • 14
  • 15
  • 16
  • 17
  • 18
  • 19
  • 20
  • 21
  • 22
  • 23
  • 24
  • 25
  • 26
  • 27
  • 28
  • 29
  • 30
  • 31
  • 32
  • 33
  • 34
  • 35
  • 36
  • 37
  • 38
  • 39
  • 40
  • 41
  • 42
  • 43
  • 44
  • 45
  • 46
  • 47
  • 48
  • 49
  • 50
  • 51
  • 52
  • 53
  • 54
  • 55
  • 56
  • 57
  • 58
  • 59
  • 60
  • 61
  • 62
  • 63
  • 64
  • 65
  • 66
  • 67
  • 68
  • 69
  • 70
  • 71
  • 72
  • 73
  • 74
  • 75
  • 76
  • 77
  • 78
  • 79
  • 80
  • 81
  • 82
  • 83
  • 84
  • 85
  • 86
  • 87
  • 88
  • 89
  • 90
  • 91
  • 92
  • 93
  • 94
  • 95
  • 96
  • 97
  • 98
  • 99
  • 100
  • 101
  • 102
  • 103
  • 104
  • 105
  • 106
  • 107
  • 108
  • 109
  • 110
  • 111
  • 112
  • 113
  • 114
  • 115
  • 116
  • 117
  • 118
  • 119
  • 120
  • 121
  • 122
  • 123
  • 124
  • 125
  • 126
  • 127
  • 128
  • 129
  • 130
  • 131
  • 132
  • 133
  • 134
  • 135
  • 136
  • 137
  • 138
  • 139
  • 140
  • 141
  • 142
  • 143
  • 144
  • 145
  • 146
  • 147
  • 148
  • 149
  • 150
  • 151
  • 152
  • 153
  • 154
  • 155
  • 156
  • 157
  • 158
  • 159
  • 160
  • 161
  • 162
  • 163
  • 164
  • 165
  • 166
  • 167
  • 168
  • 169
  • 170
  • 171
  • 172
  • 173
  • 174
  • 175
  • 176

The following table details the sales of key products.
Percent change
At actual At constant
currency currency
rates rates
years ended December 31 (in millions) 2013 2012 2011 2013 2012 2013 2012
HUMIRA
United States $ 5,236 $ 4,377 $ 3,427 20% 28% 20% 28%
International 5,423 4,888 4,505 11% 8% 12% 15%
Total $10,659 $ 9,265 $ 7,932 15% 17% 15% 21%
AndroGel
United States $ 1,035 $ 1,152 $ 874 (10)% 32% (10)% 32%
Kaletra
United States $ 244 $ 279 $ 326 (13)% (14)% (13)% (14)%
International 718 734 844 (2)% (13)% (1)% (7)%
Total $ 962 $ 1,013 $ 1,170 (5)% (13)% (4)% (9)%
Synagis
International $ 827 $ 825 $ 775 — 6% 9% 9%
Lupron
United States $ 566 $ 569 $ 540 (1)% 5% (1)% 5%
International 219 231 270 (5)% (14)% (3)% (11)%
Total $ 785 $ 800 $ 810 (2)% (1)% (1)% —
Synthroid
United States $ 622 $ 551 $ 522 13% 6% 13% 6%
Sevoflurane
United States $ 77 $ 82 $ 88 (5)% (7)% (5)% (7)%
International 491 520 577 (6)% (10)% (4)% (5)%
Total $ 568 $ 602 $ 665 (6)% (10)% (4)% (5)%
Creon
United States $ 412 $ 353 $ 332 17% 6% 17% 6%
Duodopa
International $ 178 $ 149 $ 125 20% 19% 16% 29%
Dyslipidemia products
United States $ 1,076 $ 2,145 $ 2,504 (50)% (14)% (50)% (14)%
Other $ 1,666 $ 1,525 $ 1,735 9% (12)% 10% (11)%
Total $18,790 $18,380 $17,444 2% 5% 3% 8%
On a constant currency basis, global HUMIRA sales increased 15 percent in 2013 and 21 percent in
2012 as a result of market expansion and higher market share across various countries, higher pricing
in certain geographies and the global launch of the ulcerative colitis indication in 2012. HUMIRA sales
continued to expand in the rheumatology, dermatology and gastroenterology categories. HUMIRA
received approvals from the European Commission for the treatment of moderately to severely
active ulcerative colitis in April 2012, the treatment of severe axial spondyloarthritis in July 2012, and
the treatment of pediatric patients with severe active Crohn’s disease in November 2012. AbbVie is
pursuing several new indications to help further differentiate from competitive products and add to the
sustainability and future growth of HUMIRA.
AndroGel sales for 2013 were impacted by rebates implemented during the second half of 2012, certain
account losses in early 2013 and continued moderation of market growth. The increase in AndroGel
41